Lynx1 Capital Management LP — SEC insider filings
SEC reporting owner CIK 1910456. 19 insider filings on record with FilingPulse; latest filed 2026-10-26.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2023-06-02 to 2026-10-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 35 legs across 16 filings — 6,524,431 shares, $22,905,901 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 25,400 shares, $63,952 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: purchase of 626,043 shares @ $6.70 ($4,191,859) in Cullinan Therapeutics, Inc., filed 2025-10-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 10% owner | 3 | 8 legs · 1,874,057 sh · $13,322,539 | — | — |
| TScan Therapeutics, Inc. (TCRX) | 10% owner | 7 | 8 legs · 2,883,342 sh · $3,641,962 | 3 legs · 25,400 sh · $63,952 | 2 |
| Neuphoria Therapeutics Inc. (NEUP) | 10% owner | 1 | 1 leg · 639,110 sh · $3,283,108 | — | — |
| Passage BIO, Inc. (PASG) | 10% owner | 5 | 11 legs · 1,040,909 sh · $1,689,220 | — | — |
| Korro Bio, Inc. (KRRO) | 10% owner | 3 | 7 legs · 87,013 sh · $969,073 | — | — |
Insider filings — Lynx1 Capital Management LP
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Korro Bio, Inc. (KRRO) jointly with Nichols Weston | Purchase (P): 12,175 @ $9.68 · Purchase (P): 40,000 @ $11.04 · Purchase (P): 2,510 @ $12.11 · Purchase (P): 25,124 @ $11.75 | EDGAR |
| 2026-08-13 | 4 | Korro Bio, Inc. (KRRO) jointly with Nichols Weston | Purchase (P): 5,222 @ $11.40 · Purchase (P): 1,462 @ $13.19 | EDGAR |
| 2026-06-29 | 4 | Passage BIO, Inc. (PASG) jointly with Nichols Weston | Purchase (P): 50,055 @ $4.12 | EDGAR |
| 2026-04-02 | 4 | Korro Bio, Inc. (KRRO) jointly with Nichols Weston | Purchase (P): 520 @ $10.60 | EDGAR |
| 2025-12-23 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 80,069 @ $0.90 · Purchase (P): 75,500 @ $0.90 · Purchase (P): 6,232 @ $0.90 | EDGAR |
| 2025-10-30 | 4 | Cullinan Therapeutics, Inc. (CGEM) jointly with Nichols Weston | Purchase (P): 165,667 @ $8.40 | EDGAR |
| 2025-10-23 | 4 | Neuphoria Therapeutics Inc. (NEUP) jointly with Nichols Weston | Purchase (P): 639,110 @ $5.14 | EDGAR |
| 2025-10-21 | 4 | Cullinan Therapeutics, Inc. (CGEM) jointly with Nichols Weston | Purchase (P): 15,032 @ $7.59 · Purchase (P): 51,500 @ $7.94 · Purchase (P): 150,000 @ $8.86 · Purchase (P): 32,217 @ $7.84 | EDGAR |
| 2025-10-10 | 4 | Cullinan Therapeutics, Inc. (CGEM) jointly with Nichols Weston | Purchase (P): 556,300 @ $6.46 · Purchase (P): 626,043 @ $6.70 · Purchase (P): 277,298 @ $7.36 | EDGAR |
| 2025-09-15 | 4 | Passage BIO, Inc. (PASG) jointly with Nichols Weston | Purchase (P): 325 @ $6.96 · Purchase (P): 19,783 @ $6.99 · Purchase (P): 11,900 @ $6.99 | EDGAR |
| 2025-07-24 | 4 | Passage BIO, Inc. (PASG) jointly with Nichols Weston | Purchase (P): 13,123 @ $5.44 · Purchase (P): 49,302 @ $5.74 · Purchase (P): 66,423 @ $5.71 | EDGAR |
| 2025-05-21 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 1,388,794 @ $1.20 · Purchase (P): 1,200,000 @ $1.20 | EDGAR |
| 2024-12-31 | 4 | Passage BIO, Inc. (PASG) jointly with Nichols Weston | Purchase (P): 373,645 @ $0.65 | EDGAR |
| 2024-12-30 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 7,500,000 (derivative) @ $4 | EDGAR |
| 2024-12-16 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 31,800 @ $3.01 · Purchase (P): 100,000 @ $2.90 | EDGAR |
| 2024-11-27 | 4 | Passage BIO, Inc. (PASG) jointly with Nichols Weston | Purchase (P): 259,998 @ $0.56 · Purchase (P): 167,055 @ $0.71 · Purchase (P): 29,300 @ $0.67 | EDGAR |
| 2024-11-19 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 947 @ $4.34 | EDGAR |
| 2024-04-23 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Purchase (P): 5,000,000 (derivative) @ $7.13 | EDGAR |
| 2023-06-02 | 4 | TScan Therapeutics, Inc. (TCRX) jointly with Nichols Weston | Sale (S): 10,000 @ $2.51 · Sale (S): 15,000 @ $2.52 · Sale (S): 400 @ $2.51 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-12-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1910456 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs